Over the last 12 months, CRISPR Therapeutics insiders reported no purchases and 23 sales totaling $17.9M across SEC Form 4 filings. 30% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Decision | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 47,837 | $49.78 | $2.4M | -13.3% | — |
| Oct 14, 2026 | George SimeonD | ▼ Sale | Non-discretionary10b5-1 plan | 14,514 | $49.63 | $720K | -48.4% | — |
| Oct 14, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | Non-discretionarytax on vesting | 1,040 | $49.26 | $51K | -1.1% | — |
| Oct 14, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 4,098 | $49.26 | $202K | -1.6% | — |
| Oct 6, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | Non-discretionary10b5-1 plan | 1,990 | $60.04 | $119K | -2.1% | — |
| Sep 22, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | Non-discretionary10b5-1 plan | 10,400 | $60.24 | $626K | -9.9% | — |
| Sep 17, 2026 | Behbahani AliD | ▼ Sale | Non-discretionaryexercise cover | 13,679 | $57.09 | $781K | -45.1% | — |
| May 29, 2026 | Patel NaimishChief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 3,786 | $55.62 | $211K | -16.4% | — |
| Mar 23, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | Non-discretionarytax on vesting | 3,182 | $46.78 | $149K | -3.3% | — |
| Mar 23, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 10,020 | $46.78 | $469K | -3.8% | — |
| Mar 23, 2026 | Prasad RajuChief Financial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 3,708 | $46.78 | $173K | -19.2% | — |
| Mar 16, 2026 | Patel NaimishChief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 3,150 | $48.26 | $152K | -19.3% | — |
| Mar 16, 2026 | Prasad RajuChief Financial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 9,869 | $48.26 | $476K | -41.7% | 2 tranches |
| Mar 16, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | Non-discretionarytax on vesting | 3,450 | $48.26 | $166K | -3.6% | — |
| Mar 16, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 10,349 | $48.26 | $499K | -4% | — |
| Mar 11, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | Non-discretionarytax on vesting | 2,800 | $52.8 | $148K | -3.1% | — |
| Mar 11, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 9,798 | $52.8 | $517K | -4% | — |
| Feb 19, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 6,967 | $52.58 | $366K | -3% | — |
| Feb 19, 2026 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | Non-discretionarytax on vesting | 2,112 | $52.58 | $111K | -2.4% | — |
| Jan 22, 2026 | Prasad RajuChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 34,972 | $60.19 | $2.1M | -83.8% | — |
| Jan 22, 2026 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionary10b5-1 plan | 90,000 | $57.4 | $5.2M | -40.1% | 3 tranches |
| Jan 6, 2026 | Prasad RajuChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 29,700 | $60.16 | $1.8M | -81.4% | 3 tranches |
| Dec 22, 2025 | Prasad RajuChief Financial Officer · O | ▼ Sale | Non-discretionary10b5-1 plan | 10,000 | $55.95 | $560K | -59.6% | 3 tranches |
| Oct 17, 2025 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 50,895 | $67.91 | $3.5M | -16.7% | — |
| Oct 14, 2025 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 4,242 | $66.6 | $283K | -2% | — |
| Oct 14, 2025 | KASINGER JAMES R.General Counsel and Secretary · O | ▼ Sale | Non-discretionarytax on vesting | 1,076 | $66.6 | $72K | -1.3% | — |
| Aug 18, 2025 | Kulkarni SamarthChief Executive Officer · O·D | ▼ Sale | Non-discretionarytax on vesting | 13,081 | $58.15 | $761K | -5.9% | — |
| Apr 3, 2025 | Patel NaimishChief Medical Officer · O | ▲ Buy | — | 1,508 | $32.96 | $50K | — | late |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? CRISPR Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CRSP feed.